KalVista Pharmaceuticals (NASDAQ:KALV) Now Covered by Bank of America

Bank of America started coverage on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a research report report published on Wednesday morning, Marketbeat reports. The firm issued a buy rating and a $22.00 target price on the specialty pharmaceutical company’s stock.

A number of other analysts have also weighed in on KALV. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Finally, Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th.

KalVista Pharmaceuticals Price Performance

KALV traded down $0.12 during trading on Wednesday, hitting $8.34. 36,651 shares of the stock traded hands, compared to its average volume of 475,137. The firm has a market capitalization of $412.15 million, a P/E ratio of -2.29 and a beta of 0.85. KalVista Pharmaceuticals has a 12-month low of $8.24 and a 12-month high of $16.88. The firm has a 50-day moving average of $10.49 and a 200 day moving average of $11.69.

Insider Buying and Selling

In other news, insider Paul K. Audhya sold 8,077 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $74,793.02. Following the sale, the insider now directly owns 94,199 shares of the company’s stock, valued at $872,282.74. This represents a 7.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Benjamin L. Palleiko sold 7,627 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $9.75, for a total transaction of $74,363.25. Following the transaction, the chief executive officer now directly owns 274,596 shares of the company’s stock, valued at approximately $2,677,311. This trade represents a 2.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,291 shares of company stock valued at $304,086 over the last three months. Corporate insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. nVerses Capital LLC purchased a new stake in shares of KalVista Pharmaceuticals in the 2nd quarter worth approximately $25,000. China Universal Asset Management Co. Ltd. boosted its holdings in KalVista Pharmaceuticals by 67.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after acquiring an additional 3,328 shares in the last quarter. Intech Investment Management LLC bought a new stake in KalVista Pharmaceuticals in the third quarter worth $126,000. SG Americas Securities LLC purchased a new stake in shares of KalVista Pharmaceuticals in the third quarter worth $153,000. Finally, Quest Partners LLC bought a new position in shares of KalVista Pharmaceuticals during the third quarter valued at $175,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).